Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Argus Analyst Says

Amgen (NASDAQ:AMGN) had its target price hoisted by investment analysts at Argus from $360.00 to $400.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Argus’ target price would indicate a potential upside of 4.11% from the company’s current price.

Other equities research analysts have also issued research reports about the company. Morgan Stanley upped their price target on Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday. HSBC reiterated a “buy” rating and set a $425.00 price objective on shares of Amgen in a research report on Wednesday, December 10th. Oppenheimer set a $400.00 price objective on Amgen and gave the company an “outperform” rating in a research report on Thursday, January 29th. UBS Group increased their target price on shares of Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $351.65.

Amgen Stock Performance

Shares of AMGN stock opened at $384.20 on Friday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.99. The company has a market cap of $206.88 billion, a P/E ratio of 27.00, a P/E/G ratio of 3.90 and a beta of 0.46. The firm has a 50-day moving average of $334.45 and a 200-day moving average of $311.49. Amgen has a one year low of $261.43 and a one year high of $385.12.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company’s revenue was up 8.6% on a year-over-year basis. During the same period in the prior year, the business posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts forecast that Amgen will post 20.62 EPS for the current fiscal year.

Insider Activity

In related news, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the sale, the executive vice president directly owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This represents a 14.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 890 shares of Amgen stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the transaction, the senior vice president owned 7,082 shares of the company’s stock, valued at $2,381,251.68. The trade was a 11.16% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 10,908 shares of company stock valued at $3,674,966. 0.76% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AMGN. Associated Banc Corp lifted its stake in shares of Amgen by 1.0% in the 4th quarter. Associated Banc Corp now owns 23,515 shares of the medical research company’s stock valued at $7,697,000 after purchasing an additional 223 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Amgen by 2.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 19,555 shares of the medical research company’s stock valued at $6,401,000 after buying an additional 423 shares in the last quarter. New Millennium Group LLC lifted its position in Amgen by 49.1% during the 4th quarter. New Millennium Group LLC now owns 629 shares of the medical research company’s stock worth $206,000 after acquiring an additional 207 shares in the last quarter. Delta Financial Advisors LLC lifted its position in shares of Amgen by 4.1% during the fourth quarter. Delta Financial Advisors LLC now owns 10,301 shares of the medical research company’s stock worth $3,372,000 after purchasing an additional 407 shares in the last quarter. Finally, Americana Partners LLC boosted its position in Amgen by 31.4% in the 4th quarter. Americana Partners LLC now owns 17,085 shares of the medical research company’s stock valued at $5,592,000 after buying an additional 4,081 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.